Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameEc Healthcare
Stock Code02138
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities主要專注於提供醫學美容服務,如整形外科手術、微整形療程及醫生操作的能量儀器療程,並提供牙科、中醫、眼科、準醫療服務、傳統美容服務及護膚美容產品。
Listing Date2016-03-11
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港鰂魚涌英皇道979號太古坊德宏大廈20樓
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteumhgp.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 3.03 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 1e-05 / shares
Offer Period2016-03-01 to 2016-03-04
Global Offering Shares245,000,000 shares
HK Public Offer Shares (Initial)24,500,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)220,500,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO980,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share2.6%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 742,350,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 587.7M
Est. Threshold HK$ 9.44B
Analysis Result HK market cap below threshold, need +1507%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status溢利174.8百萬港元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: HKD
Income Statement
Item 2013-032014-032015-032015-09
Revenue 229,666,107489,412,925621,089,610335,868,324
Cost of sales -42,276,993-42,901,302-47,585,730-22,255,312
Other income and gains, net 12,993,3918,332,5875,705,724898,983
Selling and distribution expenses -28,434,139-23,805,197-23,928,266-16,955,502
Net finance costs -936,186-512,428-889,6830
Profit before tax -31,203,78396,668,611210,596,799104,348,484
Income tax expense 2,028,01815,261,96835,819,03720,452,194
Profit for the year -33,231,80181,406,643174,777,76283,896,290
Profit attributable to owners -32,301,00381,121,682174,415,15983,471,177
Balance Sheet
Item 2013-032014-032015-032015-09
Cash and cash equivalents 52,605,99274,822,200129,884,745323,724,341
Trade and bills receivables 32,514,92121,371,44022,123,78126,778,536
Inventories 4,769,64610,410,96913,671,16126,496,040
Total current assets 286,103,400425,540,979390,098,655424,756,440
Total current liabilities 428,554,958494,311,646458,512,021469,787,944
Total equity -98,316,225-16,920,7012,953,86122,438,571
Equity attributable to owners -96,951,819-15,820,5293,691,43022,751,026
Interest-bearing borrowings 15,714,97624,640,30100
Cash Flow Statement
Item 2013-032014-032015-032015-09
Net cash from operating activities 11,549,478144,593,319158,558,02478,314,799
Net cash from investing activities -23,356,303-49,883,72317,831,64119,154,027
Net cash from financing activities 43,172,872-72,493,388-121,327,12096,548,665
Net increase in cash 31,366,04722,216,20855,062,545194,017,491
Depreciation of PP&E 9,631,53815,319,31217,707,72510,557,602
Amortisation of intangible assets 127,375390,177445,145265,494
Purchase of PP&E -21,590,920-28,359,869-23,996,509-7,913,532
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 2.98
First Day OpenHK$ 3.1
First Day Change-1.65%
First Day Volume54949000.0
First Day Turnover160996000.0
Use of Proceeds
1、約266.5百萬港元或約40%將用于在香港及大中華的其他地區成立新的醫學美容服務中心及診所以及通過有機增長擴大我們現有醫學美容服務中心及診所的規模; 2、約166.6百萬港元或約25%將用于在我們發現時機恰當時收購醫學美容中心及醫學美容診所及成立合營公司; 3、約66.6百萬港元或約10%將用于擴張我們的牙科服務業務; 4、約66.6百萬港元或約10%將用于設立我們的皮膚科相關業務線; 5、約33.3百萬港元或約5%將用于升級及提升我們的信息科技系統; 6、余額約66.6百萬港元或約10%將用于補充營運資金及用于其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
Credit Suisse (Hong Kong) Limited CE AAO017
Overall Coordinators (1)
Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (3)
Credit Suisse (Hong Kong) Limited CE AAO017 海通国际证券有限公司 CE AAF806 CGS International Securities Hong Kong Limited CE AAW351
Joint Lead Managers (3)
Credit Suisse (Hong Kong) Limited CE AAO017 海通国际证券有限公司 CE AAF806 CGS International Securities Hong Kong Limited CE AAW351

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 昊海生物科技控股有限公司 77,698,290 HKD — 2.60% — 6 months 2016-09-11

Directors & Management

PositionChinese nameEnglish Name
Chairman鄧志輝—
Company Secretary梁兆棋—
No director data available.

Major Shareholders

Major Shareholders & Holdings鄧先生及Union Medical Care為控股股東,緊隨全球發售後(假設超額配股權並無獲行使)共同持有735,000,000股股份,佔已發行股本75%。
About this page

This page shows Ec Healthcare (02138) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect